BRIEF: Revenue at Salix starts to rebound

Posted on: Tue, 10 Nov 2009 06:33:00 EST


Symbols: SLXP
Nov 10, 2009 (The News and Observer - McClatchy-Tribune Information Services via COMTEX) --
SLXP | Quote | Chart | News | PowerRating -- Salix Pharmaceuticals reported stronger third-quarter sales of its drugs to treat various gastrointestinal diseases.

The Morrisville company announced Monday that revenue rose to $65.7 million, up 53 percent from the same period last year. Salix reported a net loss of $7.3 million, or 15cents a share. But the results beat the average expectation of Wall Street analysts.

Salix shares have more than tripled since March as investors grew optimistic aboutSalix. The stock closed at $21.14 Monday, up 20 cents.

Salix, one of the Triangle's most successful drug companies, has several products on the market and promising treatments in development. Salix recently hired 64 salespeople to help market its medicines to physicians.

"The third quarter of 2009 was one of the most exciting and rewarding periods in the company's history to date," CEO Carolyn Logan said.

To see more of The News & Observer, or to subscribe to the newspaper, go to
http://www.newsobserver.com. Copyright (c) 2009, The News and Observer, Raleigh,
N.C. Distributed by McClatchy-Tribune Information Services. For reprints, email
tmsreprints@permissionsgroup.com, call 800-374-7985 or 847-635-6550, send a fax
to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave.,
Suite 303, Glenview, IL 60025, USA.

For full details on Salix Pharmaceuticals Ltd (SLXP) SLXP. Salix Pharmaceuticals Ltd (SLXP) has Short Term PowerRatings at TradingMarkets. Details on Salix Pharmaceuticals Ltd (SLXP) Short Term PowerRatings is available at This Link.

UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
Thursday February 11 04:30 PM
* Attendance is strictly limited and are filled on a first-come, first-served basis.